Table 1 |
||||
| Clinical and biological characteristics of study patients by IR | ||||
| Characteristics | Total patients | Patients without IR (Group 1) | Patients with IR (Group 2) | P |
| N | 89 | 30 (33.7) | 59 (66.3) | |
| Age (years)a | 28 (22) | 20.5 (13) | 33 (25) | 0.12 |
| Males | 51 (57.3) | 14 (46.7) | 37 (62.7) | 0.14 |
| BMI (kg/m2) | 23.6 ± 3.9 | 22.6 ± 3.8 | 24.2 ± 3.8 | 0.3 |
| Fasting glucose (mg/dl) | 85.7 ± 13.7 | 82.3 ± 8.6 | 87.2 ± 15 | 0.12 |
| Haemoglobin A1c (%) | 4.85 ± 0.39 | 4.82 ± 0.25 | 4.86 ± 0.43 | 0.66 |
| Hypertensionb | 23 (25.8) | 8 (26.7) | 15 (25.4) | 1.00 |
| CD4 Tcell (cells/mm3)a | 440 (402) | 525 (470) | 428 (370) | 0.38 |
| Patients with undetectable HIV viral load | 65 (73) | 20 (66.7) | 45 (76.3) | 0.33 |
| Time on antiretroviral therapy (months)a | 72.5 (95) | 80 (120) | 70.5 (95) | 0.21 |
| Time from HIV diagnosis (months)a | 80.5 (83) | 92 (96) | 76 (64) | 0.36 |
| Current Protease Inhibitor treatment | 65 (73) | 23 (76.7) | 42 (71.2) | 0.58 |
| Total cholesterol (mg/dl) | 192 ± 38.4 | 181.9 ± 33 | 199.6 ± 39.9 | 0.04* |
| HDL cholesterol (mg/dl) | 43.9 ± 12.4 | 42.9 ± 10.5 | 44.3 ± 13.3 | 0.53 |
| LDL cholesterol (mg/dl) | 111.87 ± 35.4 | 107.3 ± 32.7 | 114.1± 36.8 | 0.39 |
| Triglycerides (mg/dl)a | 166 (129) | 151.5 (79) | 181 (169) | 0.04* |
| Dyslipidemiac | 71 (79.8) | 24 (80) | 47 (79.7) | 1.00 |
| Hypertriglyceridemiad | 54 (60.7) | 16 (53.3) | 38 (64.4) | 0.36 |
| Adiponectin (μg/mL)a | 10.2 (12.5) | 16 (28.8) | 9.4 (10.7) | 0.00* |
| Leptin (ng/mL)a | 1.4 (3.6) | 1.8 (2.9) | 1.3 (4.1) | 0.53 |
| Resistin (ng/mL)a | 5.5 (3.6) | 5.2 (5.1) | 5.7 (3.4) | 0.63 |
| TNF alfa (pg/mL)a | 10.3 (15.1) | 11.9 (16.2) | 9.7 (15) | 0.62 |
| IL-6 (pg/mL)a | 26.5 (10.3) | 26.6 (23.1) | 26.5 (8.4) | 0.52 |
Data are shown as mean ± SD or number (percent).
a Results presented as median (interquartile range).
b Hypertension defined as blood pressure ≥130/≥85 mm Hg or antihypertensive medication.
c Dyslipidemia defined as elevation of one of the following: total cholesterol, LDL cholesterol, triglyceride serum concentrations or a decrease of HDL cholesterol.
d Hypertriglyceridemia defined as serum triglycerides ≥150 mg/dl.
* p<0.05 Group 1 vs. Group 2.
p values based on t-test for equality of means or Mann–Whitney test for continuous variables, Chi-square or Fisher’s exact test for categorical variables.
Arama et al. BMC Endocrine Disorders 2013 13:4 doi:10.1186/1472-6823-13-4
